Leftover stocks of high-priced medicines are emerging as a serious headache for Japanese pharmacies, fueling financial stress and even bankruptcies…
BUSINESS
Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
Otsuka Pharmaceutical and Kyowa Hakko Kirin announced on June 29 that they have agreed to a strategic alliance in the fields of diabetes and oncology. In the field of diabetes, Kyowa Kirin will receive from Otsuka exclusive development and marketing…
To read the full story
BUSINESS
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Mitsubishi Tanabe Releases OD Tablet Form of Canalia in Japan
September 3, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…